Carregando...
Future of targeted agents in metastatic colorectal cancer
Great strides have been made in improving the outcome of patients with metastatic colorectal cancer and targeted agents are an important part of the treatment arsenal. The approved monoclonal antibodies, bevacizumab, cetuximab and panitumumab, are part of the standard of care, yet only recently have...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3834580/ https://ncbi.nlm.nih.gov/pubmed/24273599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/crc.12.52 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|